An­ti-ag­ing start­up ResTOR­bio gets $40M to fu­el Phase IIb study

ResTOR­bio, a new com­pa­ny de­vel­op­ing tech spun out of No­var­tis, has raised $40 mil­lion in a Se­ries B round to speed its an­ti-ag­ing pro­gram through the clin­ic.

The start­up, which was set up ear­li­er this year as a sub­sidiary of Boston-based PureTech Health, has brought in $65 mil­lion since its in­cep­tion. The mon­ey will be used to ad­vance the com­pa­ny’s lead im­munother­a­py pro­gram meant to re­duce res­pi­ra­to­ry tract in­fec­tions in el­der­ly sub­jects, which is al­ready in Phase IIb. Re­sults are ex­pect­ed next year.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.